- Home
- VSCO vs EWTX Comparison
VSCO vs EWTX Comparison
Compare VSCO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSCO
- EWTX
- Stock Information
- Founded
- VSCO 1977
- EWTX 2017
- Country
- VSCO United States
- EWTX United States
- Employees
- VSCO N/A
- EWTX 126
- Industry
- VSCO Clothing/Shoe/Accessory Stores
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- VSCO Consumer Discretionary
- EWTX Health Care
- Exchange
- VSCO Nasdaq
- EWTX Nasdaq
- Market Cap
- VSCO 1.6B
- EWTX 1.5B
- IPO Year
- VSCO N/A
- EWTX 2021
- Fundamental
- Price
- VSCO $23.02
- EWTX $14.35
- Analyst Decision
- VSCO Hold
- EWTX Buy
- Analyst Count
- VSCO 12
- EWTX 9
- Target Price
- VSCO $25.33
- EWTX $39.89
- AVG Volume (30 Days)
- VSCO 3.3M
- EWTX 732.7K
- Earning Date
- VSCO 08-28-2025
- EWTX 08-07-2025
- Dividend Yield
- VSCO N/A
- EWTX N/A
- EPS Growth
- VSCO 6.85
- EWTX N/A
- EPS
- VSCO 1.86
- EWTX N/A
- Revenue
- VSCO $6,265,451,000.00
- EWTX N/A
- Revenue This Year
- VSCO $2.39
- EWTX N/A
- Revenue Next Year
- VSCO $2.05
- EWTX N/A
- P/E Ratio
- VSCO $12.39
- EWTX N/A
- Revenue Growth
- VSCO 2.29
- EWTX N/A
- 52 Week Low
- VSCO $13.76
- EWTX $10.60
- 52 Week High
- VSCO $48.73
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- VSCO 60.72
- EWTX 53.47
- Support Level
- VSCO $21.91
- EWTX $13.93
- Resistance Level
- VSCO $25.47
- EWTX $14.94
- Average True Range (ATR)
- VSCO 1.11
- EWTX 0.62
- MACD
- VSCO 0.04
- EWTX 0.08
- Stochastic Oscillator
- VSCO 42.22
- EWTX 63.85
About VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.